Highest-materiality recent filing
Chiesi Group to acquire KalVista Pharmaceuticals for $27.00 per share, ~$1.9bn
Chiesi will acquire all KalVista shares for $27.00/sh cash, a 36% premium to 30-day VWAP as of April 28, 2026.
KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms
Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.
KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms
Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.
Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.
KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY
Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.
KalVista Q1: EKTERLY approved in US/UK; 460 patient start forms; positive CHMP opinion
EKTERLY (sebetralstat) FDA approved July 7, 2025; UK MHRA authorized same month; positive CHMP opinion; EU decision expected Oct 2025.
KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up
FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.
KalVista receives FDA approval for EKTERLY (sebetralstat), first oral on-demand HAE treatment
FDA approved EKTERLY for acute attacks of hereditary angioedema in patients 12+ years; first oral on-demand therapy.
KalVista COO Jebediah T. Ledell resigns effective May 12, 2025
COO Jebediah T. Ledell resigned effective immediately on May 12, 2025.
KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties
Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.
KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17
No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.
KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options
Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.
KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025
R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.
KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch
Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.
KalVista raises $60M in public offering and private placement to fund sebetralstat
Public offering of 5.5M shares at $10.00 per share for gross proceeds of $55M; net ~$51.3M.
KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025
Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.
KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M
NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.
On May 12, 2025, Jebediah T. Ledell notified KalVista Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as Chief Operating Officer of the Company, effective immediately.
Effective September 9, 2024, the Board of Directors (the “Board”) of KalVista Pharmaceuticals, Inc. (the “Company”) appointed Brian Piekos as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.
the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified
Max materiality 0.90 · Median 0.72 · Most common event earnings